Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00387517 · ClinicalTrials.gov registry record · Phase 3
Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 726
- Enrollment target
NCT00387517: Completed Phase 3 study, sponsored by Novartis.
NCT00387517 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 726 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00387517, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 726 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate the safety and efficacy of combination therapy of aliskiren/hydrochlorothiazide (HCTZ) 150/25 mg and 300/25 mg compared with HCTZ 25 mg in patients with hypertension who do not show response to HCTZ 25 mg over a 4-week period.
Interventions
- DRUG Aliskiren/HCTZ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 726 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-08 |
| Phase | Phase 3 |
What the finished NCT00387517 record still lists
NCT00387517 is an interventional study that assigns participants to a tested intervention. The registered 726 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Aliskiren/HCTZ is the first listed.
NCT00387517 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00387517 about?
NCT00387517 is a clinical study titled "Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension". The purpose of this trial is to evaluate the safety and efficacy of combination therapy of aliskiren/hydrochlorothiazide (HCTZ) 150/25 mg and 300/25 mg compared with HCTZ 25 mg in patients with hypertension who do not show response to HCTZ 25 mg over a 4-week period.
What is the current status of trial NCT00387517?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 726 participants. The study started on 2006-10. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00387517?
The interventions under investigation include: Aliskiren/HCTZ (DRUG).
Who is sponsoring clinical trial NCT00387517?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00387517's enrollment target sits among peer trials
726 490th of 2000 higher than 1,510 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06731478 · 726 participants · Phase 3
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- NCT05634967 · 725 participants
Kesimpta (Ofatumumab) Pregnancy Registry
- NCT05065216 · 728 participants · Phase 2
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
- NCT05739123 · 728 participants
Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia